ALLUVI: A DETAILED DIVE INTO RETATRUTIDE’S POTENTIAL

Alluvi, formerly LY3414901, represents a significant advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist shows remarkable impact in early clinical data, with substantial weight loss observed in